Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
Oncolytics Biotech (US:ONCY) Prnewswire·2025-09-02 21:10Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatmentsUpdated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating pelareorep's potential as a platform therapyIntravenously administered pelareorep continues to show clinical benefitSAN DIEGO, Sept. 2, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a c ...